Under a tenth of patients that would benefit from weight-loss injections like Wegovy are able to get them, caution the global health agency as it issues its inaugural recommendations on the drugs.
With over a billion individuals worldwide now obese, it is urging more widespread and fairer access to these injectable treatments.
Per projections, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"Our latest guidelines affirms that obesity is a long-term condition that can be managed with holistic and lifelong support," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key obstacles to widespread access to the injections that can aid individuals in losing considerable body mass, explains the body.
Weight-Loss Drug Scarcity
Despite the present best projected case, the production of these medications would only suffice for approximately 100 million people – under 10% of eligible patients, per the health organization.
The guideline urges governments and firms to widen availability, by measures such as voluntary licensing.
A patent on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in a number of nations in 2026.
The Way Obesity Jabs Function
The injections imitate a biological compound to reduce digestion speed, curb appetite and increase satiety so people reduce food intake.
People typically start to lose weight after several weeks of starting on the weekly injections.
Studies indicates users may regain a significant portion a year later of stopping the treatment, as their usual appetite return.
To be above a healthy weight increases your risk for experiencing diseases, including diabetes, heart disease, stroke, and some cancers.
Obesity affects individuals in all nations and was linked to 3.7 million fatalities worldwide in 2024, as per the WHO.
